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Abstract: Chimeric RNAs (chiRNAs) play many previously unrecognized roles in different diseases
including cancer. They can not only be used as biomarkers for diagnosis and prognosis of various
diseases but also serve as potential therapeutic targets. In order to better understand the roles of
chiRNAs in pathogenesis, we inserted human sequences into mouse genome and established a
knockin mouse model of the tamoxifen-inducible expression of ASTN2-PAPPA antisense chimeric
RNA (A-Pas chiRNA). Mice carrying the A-Pas chiRNA knockin gene do not display any apparent
abnormalities in growth, fertility, histological, hematopoietic, and biochemical indices. Using this
model, we dissected the role of A-Pas chiRNA in chemical carcinogen 4-nitroquinoline 1-oxide (4NQO)induced carcinogenesis of esophageal squamous cell carcinoma (ESCC). To our knowledge, we are
the first to generate a chiRNA knockin mouse model using the Cre-loxP system. The model could be
used to explore the roles of chiRNA in pathogenesis and potential targeted therapies.
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Chimeric RNAs (chiRNAs) are known as fusion transcripts because they comprise
RNA fragments derived from different genes [1,2]. Canonical chiRNAs are transcripts
of chromosomally rearranged DNA, while non-canonical chiRNAs are formed via DNAindependent mechanism such as trans-splicing or transcription readthrough. With the
development of advanced deep sequencing technologies, more non-canonical chiRNAs
have been discovered [1,3,4]. Although the precise mechanisms underlying the formation
of non-canonical chiRNA have not been completely elucidated [5,6], accumulating evidence
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indicates that chiRNAs play important roles in a broad spectrum of diseases, including
cancer [2,7]. Given their unique expression in the tissues/cells, a subgroup of chiRNAs
can serve not only biomarkers for both diagnosis and prognosis [5,8] but also potential
therapeutic targets [9].
We have previously investigated the potentials of chiRNAs as biomarkers and molecular targets in cancer [10–12]. We examined salivary exosomal GOLM1-NAA35 chiRNA
(seG-NchiRNA) in patients with esophageal squamous cell carcinoma (ESCC) and found
that seG-NchiRNA can serve as a convenient, reliable, and noninvasive biomarker for the
assessment of therapeutic response and recurrence [12]. In addition, ASTN2-PAPPAantisense
chimeric RNA (A-Pas chiRNA), which is generated by transcription read-through/splicing
or trans-splicing, is also highly expressed in ESCC but not the surrounding normal esophagus. Results derived from xenograft models indicate that A-Pas chiRNA can promote ESCC
cell spread to lymph nodes and enhance stemness through modulating OCT4. Mechanistically, A-Pas chiRNA induces cancer stemness by activating extracellular-signal-regulated
kinase 5 (ERK5)-mediated non-canonical RNA Polymerase II-Associated Factor 1 Homolog (PAF1) [11]. These findings suggest that chiRNAs could play critical roles in cancer
pathogenesis. In order to better understand the role of A-Pas chiRNA in pathogenesis as
well as the underlying molecular mechanisms, we decided to establish a mouse model
conditionally expressing A-Pas chiRNA.
The Cre-loxP-mediated recombination system has been widely used to create genetically engineered mouse models [13]. In addition, tamoxifen-induced gene expression has
been proven to be helpful for the control of conditional expressions [14–17]. In this study,
we first generated and characterized a tamoxifen-inducible A-Pas chiRNA knockin (KI)
mouse model and then induced ESCC by 4-nitroquinoline 1-oxide (4NQO). By controlling
its expression, we demonstrated the impact of A-Pas chiRNA on ESCC development.
2. Materials and Methods
2.1. Establishment and Characterization of A-Pas chiRNA Conditional Knockin Model
Mice used in this study were generated from crossing A-Pas chiRNAflox/flox mice with
CAG-CreER mice on C57BL/6 background. CAG-CreER mice were originally generated by
Jackson Model Animal Laboratory and provided by Cyagen Biosciences (Guangzhou, China).
The “CAG promoter-loxP-3*polyA-loxP-A-Pas sequence-polyA” cassette was inserted into
intron 1 of ROSA26. The targeting vector was obtained from Cyagen Biosciences (Guangzhou,
China). In the targeting vector, the Neo (neomycin resistance gene) cassette was flanked by
SDA (self-deletion anchor) sites, and DTA (diphtheria toxin A) was used for negative selection.
Correctly inserted constructs were confirmed by digestions with different restriction enzymes
and DNA sequencing (Supplementary Table S1). 3-month-old male and female mice were
administered tamoxifen (Cat. T-5648, Sigma, St. Louis, MO, USA) for 5 consecutive days
(50 mg/kg body weight; intraperitoneal injection). Mice were genotyped for floxed and Cre
alleles as well as the excised allele after tamoxifen induction using the following primers: F4
(50 -GGAAAGAACCAGCTGGGGGATATC-30 ), R4 (50 -GCCATTTAAGCCATGGGAAGTTAG30 ), and F5 (50 -TGGACAGAGGAGCCATAACTGCAG-30 ) for targeted allele; Primers F1
(50 -CATATTGGCAGAACGAAAACGC-30 ) and R1 (50 -CCTGTTTCACTATCCAGGTTACGG30 ) for Cre transgene. PCR products were separated on a 2% agarose gel to verify the DNA
size [18]. All mice were housed under strictly controlled daily lighting (12 h light/dark) at
20–22 ◦ C and 50–55% humidity and were provided ultra-filtered water and food ad libitum.
All animal procedures were approved by the Animal Care and Use Committee of Jinan
University (IACUC-20191210-03).
2.2. Targeting A-Pas chiRNA to Embryonic Stem Cells (ES Cells)
The ROSA26 targeting construct was linearized by restriction enzyme NotI (R3189L,
New England Biolabs, Ipswich, MA, USA), followed by phenol/chloroform extraction and
ethanol precipitation. The linearized vector was transfected into C57BL/6 ES cells by electroporation, and the transfected ES cells were subject to G418 selection (200 µg/mL) for 24 h.

Cells 2022, 11, 277

3 of 10

The following primers were used for screening potentially targeted clones: primers P3 (50 CAAAGCTGAAAGCTAAGTCTGCAG-30 ) and P4 (50 -GGGCCATTTACCGTAAGTTATGTA
ACG-30 ) for KI1 PCR; primers P5 (50 -CAACGTGCTGGTTATTGTGCTGTCT-30 ) and P6
(50 -TGGTGGCCACGTGTAGTGGATCC-30 ) for KI2 PCR. The positive clones (1A1, 1A8,
1A10, 1E3, 1G3, and 1H2) were expanded and further characterized by Southern blot
analysis (Supplementary Figure S2F). DNAs were digested by endonucleases, separated
by electrophoresis, transferred to a nitrocellulose membrane, and hybridized with labeled
DNA probes. All six expanded clones were confirmed to be correctly targeted.
2.3. Generation of Mice Expressing chiRNA and Breeding Scheme
Targeted ES cell clone 1E3 was injected into C57BL/6 albino embryos, which were
then re-implanted into CD-1 pseudo-pregnant females. Founder animals were identified by
their coat color, and their germline transmission was confirmed by breeding with C57BL/6
females and subsequent genotyping of the offspring. The Neo cassette is self-deleted in
germ cells so the offsprings were Neo cassette-free. F1 offspring were identified by PCR
for the presence of the A-Pas flox/+ allele using genomic DNA isolated from tail tissue. The
following primers were used for screening for KI1, KI2, KI3, and Neo deletion: F1 (50 CATATTGGCAGAACGAAAACGC-30 ) and R1 (50 -CCTGTTTCACTATCCAGGTTACGG30 ) for KI1; F2 (50 -GCATCCTCAAGGACACCAAAATCAC-30 ) and R2 (50 -GATATCCCCCAG
CTGGTTCTTTCC-30 ) for KI2; F3 (50 -CAACGTGCTGGTTATTGTGCTGTCT-30 ) and R3 (50 TGGTGGCCACGTGTAGTGGATCC-30 ) for KI3; and F4 (50 -GGAAAGAACCAGCTGGGGG
ATATC-30 ), R4 (50 -GCCATTTAAGCCATGGGAAGTTAG-30 ), and F5 (50 -TGGACAGAGGAG
CCATAACTGCAG-30 ) for neo deletion (Supplementary Figure S3A). A-Pas flox/flox, CAG-Cre
mice were generated via crossing A-Pas flox/+ mice with CAG-CreER mice. After tamoxifen
induction, A-Pas chiRNA expressions in vital organs (liver, intestines, ovary, heart, brain,
muscle, kidney, skin, tongue, stomach, lung, spleen, and esophagus) were detected by
real-time quantitative PCR (RT-qPCR) [18]. The experiment process of RT-qPCR is described as follows. Total RNA was isolated from mice tissues by the TRIzol reagent (Cat.
15596-018, ThermoFisher, Waltham, MA, USA) and reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Cat. 4368813, Applied Biosystems, Waltham, MA,
USA) according to the manufacturer’s instructions. cDNA was amplified and quantified
in the CFX Connect system (Cat. 1855200, BIO-RAD, Hercules, CA, USA) by using SYBR
Green Master (Cat. 08733/09121, CWBIO, China). Reactions were performed using a
total volume of 20 µL, which contained 1 µL of cDNA template (corresponding to 5 ng
of the starting amount of RNA), 0.2 mM each primer, and 10 µL 2× SYBR Premix Ex Taq
II. PCR cycling conditions were as follows: 94 ◦ C for 30 s, followed by 40 cycles of 94 ◦ C
for 10 s, 55–62 ◦ C for 10 s, and 72 ◦ C for 10 s in a 96-well reaction plate, and the annealing
temperature was based on the Tm value of primers. The melting curve was recorded
after 40 cycles to verify primer specificity by heating from 65 ◦ C to 95 ◦ C. Each RT-qPCR
reaction was performed in triplicate (technical replicates) on samples from three individual plants (biological replicates). cDNA was subjected to RT-qPCR with the following
primers: A-Pas chiRNA forward: 50 -CAACGTGCTGGTTATTGTGCTGTCT-30 and reverse:
50 -TGGTGGCCACGTGTAGTGGATCC-30 ; β-actin forward: 50 -GAACCCCAAGGCCAACC
GCGAGA-30 and reverse: 50 -TGACCCCGTCACCGGAGTCCATC-30 . β-actin served as a
reference gene for normalization.
2.4. Induction the Expression of ESCC Model by 4NQO with or without Expression of chiRNA
Wild type (WT) and A-Pas chiRNA KI mice (3 males and 3 females per group) weighing
20–22 g were randomly selected 4 weeks after the tamoxifen injection and anesthetized
with 50 mg/kg body weight of avertin (2, 2, 2, -Tribromoethanol, 20 mg/mL, Sigma, St.
Louis, MO, USA). Blood was collected from the canthal vein and subjected to cytological
and biochemical tests. Small pieces of liver, kidney, spleen, lung, heart, and brain were
fixed in formalin for 24 h and embedded in paraffin. After deparaffinization in xylene,
the tissue sections (5 µm) were stained with Hematoxylin and Eosin (HE) and examined
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by an experienced veterinary pathologist. Six-week-old WT and A-Pas chiRNA KI mice
treated with tamoxifen were given 100 µg/mL carcinogen 4NQO (Cat. N8141, Sigma, St.
Louis, MO, USA) in drinking water for 16 weeks [19]. Whole esophagi were longitudinally
dissected and pictured. The gross lesions (>1 mm diameter) of esophagi were counted and
fixed in formalin. The bodyweight of the mice was measured weekly.
2.5. Statistical Analysis
Student’s t-test or analysis of variance (ANOVA) followed by appropriate multiple
comparison tests using SPSS statistics 20.0 software. When p < 0.05, it is considered
statistically significant.
3. Results
3.1. Construction of the Targeting Vector
Rosa26 (NCBI Reference Sequence: NR_027008.1) is the most commonly used “safe
harbor” locus because Rosa26 encodes a nonessential nuclear RNA expressed in almost all
tissues. The conditional expression of an exogenous gene will result when a loxP-3*stoploxP sequence is inserted upstream of the exogenous sequence at the Rosa26 locus, and
this model was crossed with a Cre deleter. As illustrated in Supplementary Figure S1A,
we inserted the “CAG promoter-loxP-3*polyA-loxP-A-Pas sequence-polyA” cassette into
intron 1 of ROSA26 to build gene-edited mouse models. We used high-fidelity Taq DNA
polymerase to amplify mouse genomic fragments containing homology arms (Has) from
BAC (bacterial artificial chromosome) clone and assembled into a targeting vector together
with recombination sites and selection markers (Supplementary Figure S1B). Next, the
targeting vector was linearized with restriction enzymes and used as a PCR template.
Supplementary Figure S1C showed expected PCR bands indicating that the targeting clone
had been successfully constructed.
3.2. Generation and Screening of ES Cells
The ROSA26 targeting construct was linearized by restriction enzyme NotI, followed
by phenol/chloroform extraction and ethanol precipitation. Linearized DNA was transfected into C57BL/6 ES cells by electroporation, and transfected ES cells were subject to
G418 selection (200 µg/mL) 24 h post electroporation. One-hundred and eighty-six G418resistant clones were amplified in 96-well plates. Two 96-well plates were made, with one
of them frozen at −80 ◦ C and the other was used for DNA isolation and subsequence PCR
screening for homologous recombination. The PCR screening identified 37 potential clones
(Supplementary Figure S2A–D). The positive clones (1A1, 1A8, 1A10, 1E3, 1G3, and 1H2)
were expanded and further characterized by Southern blot analyses. DNA was digested
with either EcoNI or EcoRV and hybridized using a Neo probe, which was expected to detect the following DNA fragment from the targeted allele: ~15.13 kb (with EcoNI digestion)
and ~11.01 kb (with EcoRV digestion) (Supplementary Figure S2E,F). These results suggest
all clones are correctly targeted.
3.3. Genotyping of F1 A-Pas chiRNAflox/+ Mice
Targeted ES cell clone 1E3 was injected into C57BL/6 albino embryos and re-implanted
into CD-1 pseudo-pregnant females. Founder animals were identified by their coat color.
Their germline transmission was confirmed by breeding with C57BL/6 females and subsequent genotyping of the offspring. The Neo cassette is self-deleted in germ cells; thus,
the offspring is Neo cassette-free. As shown in Supplementary Figure S3A, KI1 (F1 and
R1), KI2 (F2 and R2), KI3 (F3 and R3), and Neo (F4 and R4 and F5 and R4) were confirmed
with the insertion of fragment pairs and Neo self-removal. Finally, three male and seven
female heterozygous mice (F1 generation: #1, #8, #9, #10, #12, #15, #18, #20, #21, and #22)
were identified as positive KI1 and KI2 (Supplementary Figure S3B,C). The A-Pas chiRNA
positive pups were reconfirmed by PCR screening for KI3 and Neo deletion (Supplementary
Figure S3D,E).
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3.4. Tamoxifen-Inducible Expression of A-Pas chiRNA
The schema of structure of A-Pas chiRNA KI mice was shown in Figure 1A. We then
crossed CAG-CreER with a responsive reporter line, R26-A-Pas chiRNA, to generate the
A-Pas chiRNAflox/flox, CAG-Cre mouse and genotyped by PCR (Figure 1B). The tamoxifen induction strategy is shown in Figure 1C (left panel). The genotypes of mice induced by tamoxifen
or vehicle are shown in Figure 1C (right panel). In order to examine A-Pas chiRNA expression in adult tissues, we treated 8-week-old to 10-week-old A-Pas chiRNAflox/flox, CAG-Cre
mice with tamoxifen for 5 days before tissue samples were collected. A-Pas chiRNA expression in the vital organs including heart, brain, lung, liver, intestine, stomach, kidney,
spleen, ovary, tongue, esophagus, muscle, and skin were significantly increased when
A-Pas chiRNAflox/flox, CAG-Cre mice were treated with tamoxifen (Figure 1D). Before tamoxifen
induction, the expression of A-Pas chiRNA could not be detected by RT-qPCR in multiple
organs of mice (Supplementary Figure S4A). These data altogether suggest that we have
successfully established a KI mouse model with inducible expression of A-Pas chiRNA.
3.5. Evaluation of the Phenotype Characterization of A-Pas chiRNA KI Mice
No significant differences between the WT and A-Pas chiRNA KI mice were observed
in body weight, fur, and other physiological indices after 8 weeks of tamoxifen treatment
(Figure 2A). The fertility of female A-Pas chiRNA KI mice was not affected by the expression
of tamoxifen-induced A-Pas chiRNA since there were no obvious changes in the average
number of pregnancies, litter size, and morbidity and mortality in A-Pas chiRNA KI mice
(Supplementary Table S2). In addition, eight physiological indexes and nine biochemical
indexes were also measured. Hematology results indicated that all measured factors were
within normal ranges, suggesting that tamoxifen-induced A-Pas chiRNA did not induce
inflammatory responses (Supplementary Table S3). There was no significant difference in
liver and kidney function indexes between the two groups (Supplementary Table S4). In
addition, HE staining of the major organs including brain, heart, liver, spleen, lung, and
kidney (Figure 2B) showed no significant difference between A-Pas chiRNA KI and WT
mice. These data altogether indicate that tamoxifen-induced A-Pas chiRNA does not affect
the general physiology of the mice.
3.6. Chemical Carcinogen-Induced A-Pas chiRNA KI Mice Mimicking Human ESCC
Next, we examined the role of A-Pas chiRNA in the carcinogenesis of ESCC when mice
were exposed to carcinogen 4NQO (Figure 3A). The mice drank water containing 4NQO
(100 µg/mL) for 16 weeks before esophageal tissues were collected. Figure 3B showed
that A-Pas chiRNA dramatically increased 4NQO-induced ESCC initiation (the number
of tumors) compared with WT mice. As previously described, the esophageal wall of
WT mice was thick, rough, and lost proper organization at the end of the 16-week 4NQO
treatment [20,21]. However, with identical treatment, the esophagi form mice expressing
A-Pas chiRNA deteriorated rapidly and exhibited multiple visible lesions (>1 mm diameter).
A-Pas chiRNA KI mice prior to tamoxifen induction were also fed with 4NQO in drinking
water to observe tumor formation during this experiment, and it was found that there was
no significant difference in tumor formation between WT mice and A-Pas chiRNA KI mice
untreated with tamoxifen (Supplementary Figure S4B). HE staining of the esophagus of WT
and A-Pas chiRNA KI mice after 4NQO treatment. The results showed that the esophageal
wall of WT mice had a loss of organization of the epithelium (dysplasia), whereas APas chiRNA KI mice exhibited the formation of esophageal squamous cell carcinoma and
the invasion of neoplastic epithelial cells into subepithelial tissues (invasive carcinoma)
(Supplementary Figure S4C). Altogether, these results indicate that A-Pas chiRNA is capable
of enhancing 4NQO-induced tumorigenesis and driving cancer cells to be more aggressive.

Cells 2022,
2022, 11,
10, 277
x FOR PEER REVIEW
Cells

6 6of
of 11
10

Figure 1. Genotyping of the A-PaschiRNA flox/flox, CAG-Cre mice. (A) Schema offlox/flox,
structure
of A-PaschiRNA KI mice. (B) Scheme
CAG-Cre
Figure 1. Genotyping of the A-Pas chiRNA
mice. (A) Schema of structure of Afor genetic lineage tracing strategy (left panel). Wild type (WT), heterozygous (hetero), and homozygous (homo) mice
Pas chiRNA KI mice. (B) Scheme for genetic lineage tracing strategy (left panel). Wild type (WT),
were clearly distinguished according
to Supplementary Figure S3A (right panel). Wild type: 617 bp (using primer F5/R4),
and homozygous
(homo)
mice were243
clearly
distinguished
according
to SupA-PaschiRNA homozygotes:heterozygous
243 bp (using(hetero),
primer F4/R4),
A-PaschiRNA
heterozygotes:
bp/617
bp (using primer
F4/R4
plementary
Figure
S3A
(right
panel).
Wild
type:
617
bp
(using
primer
F5/R4),
A-P
chiRNA
as
and F5/R4), and Cre amplicon: 413 bp (using primer F1/R1). (C) Experimental strategy for tamoxifen induction (left panel). homozygotes:
243PCR
bp (using
primer F4/R4),
A-PasThe
chiRNA
bp/617was
bp (using
primer
A-PaschiRNA expression was
detected by
after tamoxifen
induction.
PCRheterozygotes:
product of A-P243
aschiRNA
277 bp,
F4/R4
and
F5/R4),
and
Cre
amplicon:
413
bp
(using
primer
F1/R1).
(C)
Experimental
strategy
(using primer F3/R3) (right panel). (D) Quantification of the expression of A-PaschiRNA in different organs. A-PaschiRNA
was highly enriched in the adult
vital organs.
Quantification
of the
expression
A-PaschiRNA
different
of the
for tamoxifen
induction
(left panel).
A-P
expression
was in
detected
byorgans
PCR after
tamoxas chiRNAof
A-PaschiRNAflox/flox, CAG-Cre mice
after
tamoxifen
induction.
A-P
as
chiRNAs
were
normalized
to
β-actin
(ΔCt
=
Ct
(Aifen induction. The PCR product of A-Pas chiRNA was 277 bp, (using primer F3/R3) (right
panel).
PaschiRNA) − Ct (β-actin)). (D)
TheQuantification
results are shown
average fold
change
relative to liver, the lowest expression of Aof theasexpression
of A-P
as chiRNA in different organs. A-Pas chiRNA was highly
PaschiRNA in organ, using 2−ΔΔCt, which ΔΔCt = ΔCt (organ) − ΔCt (liver).
enriched in the adult vital organs. Quantification of the expression of A-Pas chiRNA in different
organs of the A-Pas chiRNAflox/flox, CAG-Cre mice after tamoxifen induction. A-Pas chiRNAs were normalized to β-actin (∆Ct = Ct (A-Pas chiRNA) − Ct (β-actin)). The results are shown as average
fold change relative to liver, the lowest expression of A-Pas chiRNA in organ, using 2−∆∆Ct , which
∆∆Ct = ∆Ct (organ) − ∆Ct (liver).

EVIEW

7 of 11
Cells 2022, 11, 277

7 of 10

Figure 2. Body weight and major organs in WT and A-Pas chiRNA KI mice. (A) Body weight of WT and
A-Pas chiRNA KI mice was measured weekly for 20 weeks. Body weight of female (n = 3 per group; left
panel) and male mice (n = 3 per group; right panel) did not differ significantly between two groups.
(B) HE staining of major organs (i.e., heart, kidney, lung, liver, brain, and spleen). Scale bar: 50 µm.

Figure 2. Body weight and major organs in WT and A-PaschiRNA KI mice. (A) Body weight of WT
and A-PaschiRNA KI mice was measured weekly for 20 weeks. Body weight of female (n = 3 per
group; left panel) and male mice (n = 3 per group; right panel) did not differ significantly between
two groups. (B) HE staining of major organs (i.e., heart, kidney, lung, liver, brain, and spleen). Scale
bar: 50 μm.
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4. Discussion
Discovery of chiRNAs has added a novel layer of complex RNA universe and provided
insights into molecular mechanisms of human diseases. Results from numerous studies
suggest that chiRNAs not only play important roles in cancer pathogenesis but also can
serve as biomarkers and therapeutic targets [10–12,22–25]. Different tools tailored explicitly
to chiRNA research have been developed [7]. However, applicable in vivo mouse models
for studying chiRNA in physiological state are lacking. Using the Cre-loxP system, we
established an in vivo model to control the expression of A-Pas chiRNA by tamoxifen in
C57BL/6 mice with a few advantages. In fact, A-Pas chiRNA KI mice are born without any
embryonic lethal, and there is no obvious pathological change in organs nor abnormal
metabolism. Since A-Pas chiRNA can be expressed at the desired time point, this model can
be used in different experiments to address specific scientific questions that other available
models could not answer. As shown in this study, controlling the expression of chiRNA
enabled us to dissect the role of A-Pas chiRNA in 4NQO-induced ESCC. Additionally, since
controlled expression of A-Pas chiRNA can occur in many organs other than the esophagus
including brain, heart, lungs, liver, stomach, colon, and spleen tissues, this model can
broaden our understanding of A-Pas chiRNA in physiological and pathological settings.
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Without the tamoxifen-inducible A-Pas chiRNA KI mouse model, we were able to show
that A-Pas chiRNA is highly enriched in ESCC [11], while whether the enriched expression
of A-Pas chiRNA is the causation or resultant of ESCC pathogenesis is still unknown. The
inducible model enabled us to show the role of A-Pas chiRNA in 4NQO-induced ESCC
initiation, evidenced by the increased number of the tumor compared with WT mice.
Previously, we demonstrated that A-Pas chiRNA can induce cancer stemness by activating
ERK5-mediated non-canonical PAF1 [11]. With this inducible model, we further showed
the enhancing effect of A-Pas chiRNA on tumor progression because cancer cells become
more malignant in the presence of A-Pas chiRNA. These findings not only support our
previous reports but enable us to understand the underlying molecular mechanism at
different levels.
One limitation of our study was that the expression of A-Pas chiRNA induced by tamoxifen occurs in multiple organs, we cannot exclude the possible effect from overexpressed
A-Pas chiRNA in the other organs. Nevertheless, studies using this animal model with a
combination of different research tools will investigate unique questions that otherwise not
be answered. To our knowledge, we are the first to establish a chiRNA KI mouse model.
The methodology used in this report will be valuable for establishing knockin animal
models of other chiRNAs.
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